New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
08:13 EDTCRMECardiome reaches agreement with Merck to reitre debt and close line of credit
Cardiome Pharma announced that the company has reached an agreement with Merck to settle its debt obligations stemming from the companies' collaboration and license agreement for vernakalant, signed in April 2009. Under the terms of the settlement agreement, Cardiome will pay Merck $20M on or before March 31, 2013, to settle its outstanding debt of $50M owed to Merck. The payment will be made from Cardiome's existing cash balance, which totalled $53.6M at the end of September. Pursuant to the vernakalant collaboration and license agreement Merck had granted Cardiome an interest-bearing credit facility of up to $100M secured by a first priority security interest in the company's vernakalant patents throughout the world and all associated proceeds. The settlement between Cardiome and Merck will terminate the credit facility and, upon payment of the $20M settlement amount, will release and discharge the collateral security taken in respect of the advances under the line of credit.
News For CRME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
14:13 EDTCRMERock springs reports 6.2% passive stake in Cardiome
July 28, 2015
16:47 EDTCRMECardiome announces approximately $15M bought deal financing
Cardiome announced that it has entered into an agreement with a syndicate of underwriters led by Cormark Securities, acting as sole bookrunner and co-lead underwriter and Canaccord Genuity Corp., acting as co-lead underwriter and including Brean Capital LLC and Laurentian Bank Securities, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 1.875M common shares from the treasury of the Company at a price of $8.00 per share, for gross proceeds of approximately $15M. The Offering is expected to close on or about August 13. Completion of the Offering is subject to, and conditional upon, the receipt of all necessary approvals, including approval of the Toronto Stock Exchange and the NASDAQ.
16:27 EDTCRMECardiome trading halted, news pending
Subscribe for More Information
July 24, 2015
08:05 EDTCRMECardiome partner Eddingpharm to initiate Brinavess Phase I study in China
Subscribe for More Information
July 22, 2015
08:06 EDTCRMECardiome submits supplemental NDS for Aggrastat in Canada
Cardiome has submitted a Supplemental New Drug Submission to Health Canada's Therapeutic Products Directorate for Aggrastat. The sNDS includes data to support High Dose Bolus administration of Aggrastat and an indication expansion for the reduction of major cardiovascular events in patients with acute myocardial infarction intended for primary PCI. Aggrastat, in combination with heparin and ASA is currently indicated in Canada for the management of patients with unstable angina or non-Q-wave myocardial infarction

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use